Relationship of SARS-CoV-2–specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.02.16.21251838: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Briefly, 400 µl whole blood was stimulated with the SARS-CoV-2 S, N and M protein peptide pool or a pool of 300 Mtb-derived peptides (Mtb300, 2 µg/ml) (Lindestam Arlehamn et al., 2016) at 37°C for 5 hours in the presence of co-stimulatory antibodies against CD28 and CD49d (1µg/ml each; BD Biosciences, San Jose, CA, USA) and Brefeldin-A (10µg/ml, Sigma-Aldrich, St Louis, MO, USA) antibodies against CD28suggested: (Novus Cat# NB100-93558, RRID:AB_1236789)CD49dsuggested: NoneBrefeldin-Asuggeste…SciScore for 10.1101/2021.02.16.21251838: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Briefly, 400 µl whole blood was stimulated with the SARS-CoV-2 S, N and M protein peptide pool or a pool of 300 Mtb-derived peptides (Mtb300, 2 µg/ml) (Lindestam Arlehamn et al., 2016) at 37°C for 5 hours in the presence of co-stimulatory antibodies against CD28 and CD49d (1µg/ml each; BD Biosciences, San Jose, CA, USA) and Brefeldin-A (10µg/ml, Sigma-Aldrich, St Louis, MO, USA) antibodies against CD28suggested: (Novus Cat# NB100-93558, RRID:AB_1236789)CD49dsuggested: NoneBrefeldin-Asuggested: NoneCells were then stained at room temperature for 45 min with antibodies for CD3 BV650, CD4 BV785, CD8 BV510, CD19-BV750 CD3suggested: NoneCD4suggested: NoneCD8suggested: NoneSoftware and Algorithms Sentences Resources Samples were acquired on a BD LSR-II and analyzed using FlowJo (v9.9.6, FlowJo LCC, Ashland, OR, USA). FlowJosuggested: (FlowJo, RRID:SCR_008520)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
